Item 1.01. Entry into a Material Definitive Agreement.

2021 Term Loan Amendment and Partial Repayment

On December 31, 2021 (Effective Date), Biodesix, Inc. (the Company) entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) by and between Silicon Valley Bank, a California corporation (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the Second Amendment, certain restrictive financial covenants were modified.

The modification of key terms under the Second Amendment to our $30 million 2021 Term Loan include the following:



?
Consent for a $4.6 million January 2022 milestone payment under the Integrated
Diagnostics APA;
?
Repayment of $20 million in outstanding principal on December 31, 2021; and
?
Waiver and elimination of $600,000 prepayment fee on the $20 million Term Loan
repayment.


Item 8.01. Other Events.

On December 30, 2021, the Company raised approximately $16.3 million in gross proceeds from the sale of 3,756,994 common shares in an at-the-market offering in order to, among other things, fund the partial repayment of the 2021 Term Loan.

The Company issued a press release announcing the sale of common shares under an at-the-market offering and the execution of the Second Amendment to the Loan and Security Agreement and subsequent partial repayment of the outstanding principal under the 2021 Term Loan, which provides the Company additional financial flexibility over the near term to advance its strategic growth objectives. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 8.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:



 No.      Exhibit
10.40       Consent and Second Amendment to Loan and Security Agreement
99.1        Press Release issued by Biodesix, Inc. dated January 4, 2022
 104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses